Bayer and Versant Ventures launch stem cell business BlueRock Therapeutics

Bayer has announced the launch of a next-generation regenerative medicine company called BlueRock Therapeutics, in partnership with Versant Ventures.

The two companies are committing $225 million (177.05 million pounds) to establish the new company's platform and pipeline, representing one of the largest-ever series A financings for a biotechnology company.

This will provide BlueRock Therapeutics with at least four years of runway, allowing it to advance a number of programmes into the clinic, with an initial focus on cardiovascular diseases and neurodegenerative disorders.

Its overall goal will be to develop best-in-class induced pluripotent stem cell therapies to cure a range of diseases, using an industry-leading platform, supported by strategic partnerships with leading academic and industry collaborators in the US, Canada and Japan.

BlueRock Therapeutics will be led by a world-class team, with representatives of both Bayer and Versant among its board members.

Kemal Malik, member of the board of management of Bayer responsible for innovation, said: "We are launching this enterprise to develop transformative and curative therapies for patients based on the latest stem cell technology."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.